Business
The firms, which are developing cancer vaccines, are going public at a tough time for biotech stocks.
Oct. 27, 2003
CancerVax Corp. stock plunged Tuesday after the biotechnology company announced that it would toss aside its most advanced drug candidate and slash its workforce by more than half.
Oct. 5, 2005
A California biotech company is seeking U.S. permission to license a promising Cuban cancer drug that is barred from the U.S. by trade sanctions, Cuban scientists said at a biotechnology conference this week.
Nov. 26, 2003
CancerVax Corp., a Carlsbad company that is developing cancer treatments, raised $72 million in an initial public offering, selling 6 million shares at $12 each, at the bottom of the $12-to-$14-a-share price range the company had indicated in a Securities and Exchange Commission filing.
Oct. 30, 2003
Genitope Corp. shares closed higher and CancerVax Corp. shares were unchanged on their first day of trading Thursday.
Oct. 31, 2003
Technology and the Internet
Funding: Fourth quarter saw a 28% decrease in backing in Los Angeles, Orange counties. In L.A. County, the Internet sector received 57% of the money.
Feb. 5, 2001
Anybody looking at the biotech industry these days could easily conclude that it has been a big bust.
Feb. 2, 2003
In a firm named Hybritech, San Diego discovered the formula for biotech success
Sept. 6, 2003
Obituaries
He developed sentinel lymph node evaluation, which saves the U.S. healthcare system more than $3.8 billion per year in the treatment of melanoma and breast cancer, as well as preventing countless unnecessary surgeries.
Jan. 17, 2014
Financing: ’99 was a good year for the industry, boding well for firms seeking investors at today’s conference.
Feb. 7, 2000